In a previous study, we designed and synthesized a novel PI3K/mTOR dual inhibitor, 2,4-difluoro-N-(5-(1-(4-(2-hydroxyethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide (DHW-221), and we demonstrated that it exerts a remarkable antitumor activity in NSCLC cells (23, 24). The gene discussed is MTOR; the disease is non-small cell lung carcinoma.